Méndez-Luna David, Morelos-Garnica Loreley Araceli, García-Vázquez Juan Benjamín, Bello Martiniano, Padilla-Martínez Itzia Irene, Fragoso-Vázquez Manuel Jonathan, Dueñas González Alfonso, De Pedro Nuria, Gómez-Vidal José Antonio, Mendoza-Figueroa Humberto Lubriel, Correa-Basurto José
Laboratorio de Diseño y Desarrollo de Nuevos Fármacos e Innovación Biotecnológica (Laboratory for the Design and Development of New Drugs and Biotechnological Innovation), Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, s/n, Col. Casco de Santo Tomas, Ciudad de México 11340, Mexico.
Departamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional Zacatenco, Av. Wilfrido Massieu 399, Col. Nueva Industrial Vallejo, Alcaldía Gustavo A. Madero, Ciudad de México 07738, Mexico.
Pharmaceuticals (Basel). 2021 Jan 10;14(1):49. doi: 10.3390/ph14010049.
The implementation of chemo- and bioinformatics tools is a crucial step in the design of structure-based drugs, enabling the identification of more specific and effective molecules against cancer without side effects. In this study, three new compounds were designed and synthesized with suitable absorption, distribution, metabolism, excretion and toxicity (ADME-tox) properties and high affinity for the G protein-coupled estrogen receptor (GPER) binding site by in silico methods, which correlated with the growth inhibitory activity tested in a cluster of cancer cell lines. Docking and molecular dynamics (MD) simulations accompanied by a molecular mechanics/generalized Born surface area (MMGBSA) approach yielded the binding modes and energetic features of the proposed compounds on GPER. These in silico studies showed that the compounds reached the GPER binding site, establishing interactions with a phenylalanine cluster (F206, F208 and F278) required for GPER molecular recognition of its agonist and antagonist ligands. Finally, a 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay showed growth inhibitory activity of compounds , and in three different cancer cell lines-MIA Paca-2, RCC4-VA and Hep G2-at micromolar concentrations. These new molecules with specific chemical modifications of the GPER pharmacophore open up the possibility of generating new compounds capable of reaching the GPER binding site with potential growth inhibitory activities against nonconventional GPER cell models.
化学信息学和生物信息学工具的应用是基于结构的药物设计中的关键一步,能够识别出针对癌症更具特异性和有效性且无副作用的分子。在本研究中,通过计算机模拟方法设计并合成了三种新化合物,它们具有合适的吸收、分布、代谢、排泄和毒性(ADME - 毒理学)特性,并且对G蛋白偶联雌激素受体(GPER)结合位点具有高亲和力,这与在一组癌细胞系中测试的生长抑制活性相关。对接和分子动力学(MD)模拟结合分子力学/广义玻恩表面积(MMGBSA)方法,得出了所提出化合物在GPER上的结合模式和能量特征。这些计算机模拟研究表明,这些化合物能够到达GPER结合位点,并与GPER分子识别其激动剂和拮抗剂配体所需的苯丙氨酸簇(F206、F208和F278)建立相互作用。最后,3 -(4,5 - 二甲基噻唑 - 2 - 基)-2,5 - 二苯基四氮唑溴盐(MTT)试验表明,化合物、和在微摩尔浓度下对三种不同的癌细胞系——MIA Paca - 2、RCC4 - VA和Hep G2具有生长抑制活性。这些对GPER药效团进行特定化学修饰的新分子,为生成能够到达GPER结合位点并对非传统GPER细胞模型具有潜在生长抑制活性的新化合物开辟了可能性。